Based on the aggregated intelligence of 125,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical radiation equipment maker Accuray (NASDAQ:ARAY) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Accuray's business, and see what CAPS investors are saying about the stock right now.

Accuray facts 

Headquarters (founded)

Sunnyvale, Calif. (1990)

Market Cap

$264 million

Industry

Health-care equipment

TTM Revenue

$223.2 million

Management

President/CEO Euan Thomson
Founder/Chief Medical Officer John Adler Jr.

Compound Annual Revenue Growth (over last two years)

51.8%

Competitors

Varian Medical Systems (NYSE:VAR)
Siemens (NYSE:SI)

CAPS members bullish on ARAY also bullish on

General Electric (NYSE:GE)
Apple (NASDAQ:AAPL)

CAPS members bearish on ARAY also bearish on

General Motors (NYSE:GM)
Crocs (NASDAQ:CROX)

Sources: Capital IQ (a division of Standard & Poor's) and Motley Fool CAPS. TTM = trailing 12 months.

Over on CAPS, 451 of the 470 members who have rated Accuray -- or 96% -- believe the stock will outperform the S&P 500 going forward. These bulls include Theresewin and FishTaleII.

In late December, Theresewin touched on Accuray's non-invasive tumor-targeting tool: "The Cyberknife technology is the future in use now ... this company has plenty of upside growth and I want to own this stock before it takes off."

In a more detailed pitch from July, FishTaleII cites the stock's beaten down price (which is even cheaper today) as a great opportunity. Here's an excerpt:

Accuray's Cyberknife is truly a breakthrough technology for eliminating tumors inoperable, or not, with little to no collateral damage to the surrounding tissue or organs. Apparently, the street does not understand the significance of this technology.... And that misunderstanding is creating a real opportunity as the stock has been beaten down from its' IPO over a year ago into the $6's today….

When the reality of how successful the technology is in destroying tumors, cancerous or otherwise, without surgery, in a very short time-frame (days), [Accuray] should finally breakout of the current trend....

The Cyberknife should not be compared to the conventional radiation treatment systems. It is in a league of its' own.

What do you think about Accuray, or any other stock for that matter? Make your voice heard on Motley Fool CAPS today. More than 125,000 investors are waiting to hear what you have to say. CAPS is 100% free, so simply click here to get started.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Apple is a Motley Fool Stock Advisor pick. The Fool's disclosure policy always gets a perfect score.